Patient baseline characteristics
| Characteristics | Overall population |
| N=19 | |
| No. (%) | |
| Sex | |
| Male | 10 (53) |
| Female | 9 (47) |
| Age (years) | |
| Median | 58 |
| Range | (35–85) |
| Mutation BRAF status | |
| Non-mutant | 8 (42) |
| Mutant | 10 (53) |
| Unknown | 1 (5) |
| Lactate dehydrogenase | |
| Normal* | 10 (53) |
| Elevated | 9 (47) |
| M staging: extent of metastases | |
| M0 | 3 (16) |
| M1a | 2 (11) |
| M1b | 6 (32) |
| M1c | 8 (42) |
| Brain metastases | |
| No | 19 (100) |
| Yes | 0 (0) |
| Site of irradiated lesions | |
| Lymph nodes | 9 (47) |
| Subcutaneous nodules | 10 (53) |
| Visceral organs | 0 (0) |
| Previous treatments† | |
| No prior systemic treatment | 0 (0) |
| Ipilimumab | 0 (0) |
| Chemotherapy | 7 (37) |
| Anti-BRAF | 8 (24) |
| Radiotherapy | 1 (5) |
| Surgery | 16 (84) |
*The normal range for lactate dehydrogenase is <247 UI/L.
†All patients were naïve to immune checkpoint inhibitors.